Medicenna Therapeutics Corp. (NASDAQ:MDNA) Q4 2022 Earnings Conference Call June 22, 2022 8:30 AM ET

Company Participants

Dan Ferry - IR, LifeSci Advisors

Fahar Merchant - President & CEO

Martin Bexon - CMO

Liz Williams - CFO

Conference Call Participants

Matt Biegler - Oppenheimer

David Martin - Bloom Burton

Catherine Novack - JonesTrading

Swayampakula Ramakanth - H.C. Wainwright

Andre Uddin - Mackie Research Capital

Shubhendu Roy - Brookline Capital Markets

David Bautz - Zacks Small-Cap Research

Operator

Hello, and welcome to the Medicenna Therapeutics Fiscal Year-End Earnings Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. [Operator Instructions] Please be advised that this call is being recorded at the company’s request.

I would now like to turn the call over to Dan Ferry of LifeSci Advisors. Dan, please go ahead.

Dan Ferry

Thank you, operator, and thank you all for participating in today's conference call. This morning, Medicenna issued a press release providing financial results and corporate updates for the fiscal year ended March 31, 2022. If you have not yet seen the press release, it is available on the Investors page of Medicenna’s website.

Before we begin, I would like to remind you that certain statements and information shared during this call constitute forward-looking information within the meaning of applicable securities laws. All statements other than statements of historical facts shared during this call, and that relate to the future operations of the company, and other statements that are not historical facts, including statements related to the clinical potential and development of MDNA11, MDNA55, and the BiSKITs programs, potential of the Superkine platform, partnering activities, cash runway, the presentation of additional data and other milestones.

Our forward-looking statements that are subject to risks and uncertainties. There could be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the company's expectations, include the risks detailed in the recently filed Annual Information Form, Management's Discussion and Analysis and Form 20-F of the company, and in other filings made by the company with the applicable securities regulators from time to time in Canada and the United States.

Listeners are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the company. You are cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect, and actual results may differ materially from those anticipated.